Dawn M. Cleaver

Learn More
OBJECTIVE To evaluate the efficacy and safety of administration of cefovecin, compared with cefadroxil, for treatment of naturally occurring secondary superficial pyoderma, abscesses, and infected wounds in dogs. DESIGN Multicenter, randomized, positive-controlled clinical trial. ANIMALS 235 client-owned dogs. PROCEDURES Dogs with clinical signs of(More)
BACKGROUND Oclacitinib is safe and effective for treating dogs with pruritus associated with allergic and atopic dermatitis, based on randomized clinical trials of up to 4 months duration. HYPOTHESIS/OBJECTIVES This study assessed long-term safety, efficacy and quality of life of oclacitinib-treated dogs enrolled in a compassionate use programme. (More)
OBJECTIVE To evaluate the effectiveness and safety of cefovecin sodium in the treatment of cats with naturally occurring skin infections (abscesses and infected wounds). DESIGN Multicenter (26 sites), randomized, double-blind, controlled clinical trial. ANIMALS Client-owned cats of any breed with naturally occurring skin infections with associated(More)
BACKGROUND Oclacitinib (Apoquel(®) ) inhibits the function of a variety of pro-inflammatory, pro-allergic and pruritogenic cytokines that are dependent on Janus kinase enzyme activity. Oclacitinib selectively inhibits Janus kinase 1. HYPOTHESIS/OBJECTIVES We aimed to evaluate the safety and efficacy of oclacitinib for the control of pruritus associated(More)
BACKGROUND Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Preliminary study results suggest that oclacitinib, a selective Janus kinase inhibitor, could reduce pruritus and associated inflammatory skin lesions in dogs with AD. HYPOTHESIS/OBJECTIVES The objective was to evaluate efficacy and safety of oclacitinib (Apoquel®) for(More)
OBJECTIVE To evaluate the clinical efficacy of a single injection of tulathromycin, compared with saline (0.9% NaCl) solution-treated control calves, for treatment of induced infectious bovine keratoconjunctivitis in calves. DESIGN Clinical trial. ANIMALS 30 Holstein bull calves ranging from 5 to 6 months old and 75 to 200 kg (165 to 440 lb) with no(More)
  • 1